Document is current
Any future updates will be listed below
-
Authors
Fenton, Matthew
Yoneyama, Miki
Wennerberg, Erik
Lund, Tom
Tutt, Andrew
Melcher, Alan
Demaria, Sandra
Somaiah, Navita
- License Information
-
More Information
Article History
Received: 17 April 2025
Accepted: 10 July 2025
First Online: 24 July 2025
Competing interests
: A.T. is/has been a consultant for AstraZeneca, Merck KGaA, Artios, Pfizer and Gilead and has received grant/research support from AstraZeneca, Myriad, Medivation and Merck KGaA; is a stockholder in Inbiomotion; is also a named inventor on patents describing the use of DNA repair inhibitors and stands to gain from their development and use as part of the ICR ‘Rewards to Inventors’ scheme and also reports benefits from this scheme associated with patents for PARP inhibitors paid to A.T. research accounts at the Institute of Cancer Research. S.D.—Research funding to institution from Lytix Biopharma and Boehringer-Ingelheim, and compensation for consultant/advisory services from Lytix Biopharma, Genentech, and Johnson & Johnson Enterprise Innovation Inc. All other authors declare no financial or non-financial competing interests.
